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Background: Clofarabine alone or in combination with cyclophosphamide and etoposide has shown a good
efficacy and a tolerable toxicity profile in previous studies of children with relapsed or refractory leukaemia. This
report describes a retrospective study of 38 French patients who received clofarabine as a monotherapy or in
combination for relapsed or refractory acute lymphoblastic leukaemia (ALL) outside of clinical trials after marketing
authorization.
Methods: We retrospectively analysed data for 38 patients, up to 21 years old, attending 17 French centres. Thirty
patients received clofarabine alone or in combination for a bone marrow relapse of acute lymphoblastic leukaemia
(ALL) or refractory disease and eight patients for a high level of minimal residual disease (MRD). Survival and
response durations were estimated by the Kaplan-Meier method.
Results: For the 30 patients who received clofarabine for a bone marrow relapse of ALL (number of relapse,
1-3; median, 1), the overall remission rate (ORR) was 37%: eight complete remission (CR) and three complete
remission without platelet recovery (CRp). Ten of the 11 responding patients subsequently underwent
haematopoietic stem cell transplantation (HSCT).
Only four of the eight patients who received clofarabine while in remission for a high level of MRD, showed a
moderate improvement of MRD. Seven of these eight patients received HSCT and six of them were alive at the end
of the study. One other patient was alive without receiving HSCT.
However, clofarabine treatment was associated with a high risk of infection and hepatotoxicity. Febrile neutropenia
grade ≥ 3 was reported in 79% of patients and documented infections grade ≥ 3 occurred in nine patients (24%).
Hepatotoxicity grade 3 was reported in nine patients (24%). We observed four deaths related to treatment.
Conclusion: In our experience, the efficacy of clofarabine is poorer than previously reported. Its toxicity is high and
can be life threatening. Prospective studies on clofarabine used during earlier phases of the disease may help to
define how best this new drug can be exploited for childhood and adolescent ALL.
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Acute lymphoblastic leukaemia (ALL) is the most com-
mon form of cancer in children, responsible for approxi-
mately 30 percent of all childhood malignancies. Despite
substantial improvements in the survival of children with
ALL over the last thirty to forty years, 20 to 25% of chil-
dren relapse [1,2]. Many children with relapsed ALL
achieve a second remission, but the overall final outcome
remains unsatisfactory, with long-term overall survival
rates ranging from 15 to 50% [3]. Treatment for relapsed
ALL primarily involves many of the same chemotherapy
agents used initially, and also haematopoietic stem cell
transplantation (HSCT) [4-6]. Because of the very poor
prognosis of these patients treated with conventional
therapy, innovative treatment strategies based on the use
of novel anti-leukaemic agents are needed.
Antimetabolites are some of the most effective drugs
against haematological malignancies. One of these new
antimetabolic drugs is clofarabine (2-chloro-9(2’-deoxy-
2’-fluoro-β-D-arabinofuranosyl)adenine), a novel second-
generation purine nucleoside analogue synthesized with
the aim to overcome the limitations (neurotoxicity), but
to retain the useful properties, of fludarabine and cladri-
bine [7-11]. Its antitumour activity is due to three
mechanisms: inhibition of DNA polymerase α, inhibition
of ribonucleotide reductase and disruption of mitochon-
drial membrane integrity causing the release of proapop-
totic factors leading to programmed cell death even in
non-dividing lymphocytes.
Phase I and II studies with clofarabine as a single-agent
have been conducted in paediatric and adult patients
with multiple relapse or refractory leukaemia [12-16].
These studies have shown the safety and the efficacy of
clofarabine with an overall remission rate of 20% in
paediatric patients. The most frequently observed grade
≥ 3 adverse events were febrile neutropenia, hypokal-
aemia, elevated aspartate or alanine transaminase levels,
hyperbilirubinaemia and neutropenia. Systemic inflam-
matory response-like or cytokine release-like events, skin
rash and hand-foot syndrome were also observed.
In view of these results, clofarabine was approved by
both the Food and Drug Administration in the United
States and the European Medicinal Evaluation Agency for
the treatment of ALL in paediatric patients (≤ 21 years
old) who have relapsed or are refractory after receiving
at least two prior regimens and for who no other treat-
ment option can be expected to result in a durable
response [15].
Clofarabine inhibits the repair of DNA damage. Using
it in combination with alkylating agents such as cyclo-
phosphamide would therefore be expected to result in
enhanced cytotoxic effects. Indeed, a synergistic effect of
this type was demonstrated in vitro [17] and was subse-
quently confirmed in clinical trials [18]. Phase I and IIstudies with a combination of clofarabine, cyclophospha-
mide and etoposide were performed by Hijiya et al. and
Locatelli et al. [19,20]. The results were very encouraging
with overall remission rates (ORR) of 55% and 56%, re-
spectively, for patients with relapsed or refractory ALL.
The most common adverse events were the same as
those found for clofarabine used as a single agent. In
some cases, however, the use of clofarabine in combin-
ation was associated with severe and potentially life-
threatening hepatotoxicity [19].
This paper reports a retrospective study of 38 French
patients who received clofarabine as monotherapy or as
part of combination therapy. The patients had relapsed
or refractory ALL (30 cases) or were in remission but
with a high MRD (8 cases).Methods
Study group
Data were obtained for 38 patients from 17 paediatric
hemato-oncology French centres. This study was
approved by the Leukaemia Committee of the SFCE
(Société Française de lutte contre les Cancers et les leucé-
mies de l’Enfant et de l’adolescent). Anonymised data
were collected using a standardised Case Report Form.
All patients who received at least one course of clofara-
bine for relapsed or refractory ALL (30 cases) or for a high
MRD despite remission (8 cases), between January 1, 2006
and January 1, 2010, and who were less than 21 years
old at the time of treatment were included. No other
eligibility criteria were required. For all the patients,
demographic data, leukaemia characteristics, previous
treatments, mode of administration of clofarabine, ad-
verse events and outcome after clofarabine therapy were
collected.
The cut-off date for this analysis was September 1,
2010.Treatment
Clofarabine was administered alone to nine patients at a
dose of 52 mg/m2 daily for five days. Twenty-nine
patients received clofarabine in combination. Three dif-
ferent combinations were used. The two most widely
used combinations were 40 mg/m2/day clofarabine,
440 mg/m2/day cyclophosphamide and 100 mg/m2/day
etoposide, as reported in the study by Hijiya et al.
(21 patients) [19] and 40 mg/m2/day clofarabine,
400 mg/m2/day cyclophosphamide and 150 mg/m2/day
etoposide as reported in the study by Locatelli et al.
(5 patients) [20]. For these two treatment combinations,
all drugs were administered for five consecutive days.
The three remaining patients received clofarabine in as-
sociation with another chemotherapy. Most patients
(27 of 38) received only one course of clofarabine; seven
Table 1 Patient characteristics (N=38)
Patient characteristics Number (%)
Gender: male/female 22/16 (58%/42%)
Median age at diagnosis, years (range) 4 (0-16)
Median age at clofarabine treatment onset,
years (range)
7 (0-18)
WBC count at diagnosis x109/l (range) 7.45 (0.9-675)
Immunophenotype
B lineage 33 (87%)
T lineage 2 (5%)
Biphenotypic 3 (8%)









Refractory to initial treatment 0
Number of earlier therapies, mean (range) 2.5 (1-4)
Previous hematopoietic stem-cell transplantation 10
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four received three courses.
Response and toxicity criteria
Complete remission (CR) was defined as no detect-
able leukaemia cells in peripheral blood, M1 bone
marrow (≤ 5% blasts) and recovery of peripheral counts
(platelets ≥ 100 x 109/l and an absolute granulocyte
count (ANC) ≥ 1.0 x 109/l). CR in the absence of platelet
recovery (CRp) was defined as patients who met all the
criteria for a CR except for the recovery of platelet counts
(platelets < 100 x 109/l). Partial remission (PR) was
defined as complete disappearance of circulating blasts
and either a M2 bone marrow (> 5% and ≤ 25% blasts)
and appearance of normal progenitor cells or a M1 bone
marrow that did not qualify for CR or CRp. The overall
remission rate (ORR) was defined as the number of
patients who achieved CR or CRp divided by the number
of patients treated.
MRD was analysed by real-time quantitative-polymerase
chain reaction (RT-qPCR) analysis of “leukaemia-specific”
junctional regions of rearranged immunoglobulin (Ig)
genes and T-cell receptor (TCR) genes, according to the
ESG-MRD-ALL guidelines 2007 [21].
Adverse events (AEs) were evaluated using National
Cancer Institute’s Common Terminology Criteria for
Adverse Events (NCI CTCAE v4.0).
Statistical analysis
Quantitative variables are reported as medians and
ranges, and qualitative variables as percentages. Fisher’s
test was used for comparison of response rates. Factors
predictive of remission were assessed through univariable
logistic regression models and the odds ratio (OR) with
ninety-five percent confidence intervals (95%CI) are
reported.
The durations of survival and of response were esti-
mated by the Kaplan-Meier method; patients who did
not experience the event concerned were censored at the
date of last follow-up. Survival curves were compared
using the log-rank test.
All statistical analyses were performed on R software
(http://www.R-project.org). All statistical tests were two-
sided with type I error of 0.05.
Results
Patients and treatment
The patient characteristics at initial diagnosis are
shown in Table 1. Median age at diagnosis was 4 years
(range, 0-16); three patients were diagnosed when infants.
There were 22 boys and 16 girls. The initial diagnosis
was B lineage ALL for 33 patients, T cell ALL for two
patients and a biphenotypic ALL for the remaining three.
The median white blood cell count was 7.45 x 109/l(range, 0.9-675). Only three patients with B lineage ALL
had high-risk cytogenetic features (one t(4; 11); two with
hypodiploidy defined as less than 45 chromosomes).
Two patients had central nervous system (CNS) involve-
ment at diagnosis. The initial treatment protocol was
EORTC 58951 for 17 patients and FRALLE 2000 for
17 patients. Three patients were included in the Interfant
2006 protocol. The last patient (biclonal T cell and mye-
loid leukaemia) was treated in the acute myeloid leukae-
mia protocol (ELAM02). All patients were in CR after
primary therapy.
Thirty patients received clofarabine for a bone marrow
relapse of ALL and eight for a high MRD (seven patients
after relapse treatment and one patient for a high MRD
in CR1) (Figure 1). Of the 30 patients treated for a re-
lapse of ALL, nine patients (30%) received clofarabine as
the first treatment for relapse and twenty-one patients
(70%) had a refractory relapse with at least one previous
treatment for the relapse before clofarabine.
Nine patients were treated with clofarabine as mono-
therapy: two for high MRD and seven for a relapse of
disease. The 29 other patients received clofarabine in
combination, six for high MRD and 23 for relapse
(Figure 2).
The median interval between initial diagnosis and clo-
farabine administration was 1.8 year for the 30 patients
treated for a relapse of ALL and 2.7 years for the eight
patients treated for a high MRD.
Figure 1 Study flowchart. CR, complete remission; CRp, complete remission without platelet recovery; PR, partial remission; F, failure; NE, not
evaluable; MRD, minimal residual disease; * indicates patients alive at the end of the study; + indicates patients in palliative treatment.
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a mean of 2.5 prior therapies before clofarabine (range,
1-4). Ten patients had received a prior HSCT (five in
CR1 and five in CR2).
Response and outcome
To describe the response to treatment, the population
was separated in two groups: one group of 30 patients
treated for a bone marrow relapse of ALL and a second
group of eight patients treated for a high MRD.Figure 2 Treatment flowchart. CR, complete remission; CRp, complete re
not evaluable; MRD, minimal residual disease; * indicates patients alive at thIn the first group of 30 patients, eight achieved CR
and three CRp, giving an overall remission rate (ORR) of
37%. Twenty-one received clofarabine for a refractory
relapse with at least one previous treatment for the re-
lapse before clofarabine and nine as first treatment for
relapse. Note that these 30 patients had been heavily
pre-treated with a mean of 2.5 prior therapies, as for the
whole population. Eight patients achieved remission
after the first cycle of clofarabine, two patients after two
cycles and one after three cycles. The initial diagnosismission without platelet recovery; PR, partial remission; F, failure; NE,
e end of the study; + indicates patients in palliative treatment.
Table 2 Impact of clofarabine on patients with a high
MRD (N=8)
MRD evolution Number (%)
Improvement of one logarithm 1 (12.5%)
Improvement of less than one logarithm 3 (37.5%)
Stable 3 (37.5%)
Non evaluable 1 (12.5%)
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patients and biphenotypic ALL for the last two. Ten of
the 26 children (38%) with B ALL and one of the two
children with T ALL achieved CR or CRp. The two cases
of biphenotypic leukaemia failed to respond. Remission
was obtained for eight of the 21 patients with refractory
relapse (7 CR and 1 CRp; ORR 38%). For the nine
patients who received clofarabine as the first treatment
for relapse (five for a first relapse, three for a second re-
lapse and one for a third relapse), the ORR was 33%
(1 CR and 2 CRp). Seven patients received clofarabine as
a monotherapy and 23 received clofarabine in combin-
ation. The ORR did not differ between the combination
regimens (35%) and the use as a single agent (43%)
(p=1.00) (Figure 2). In this first group of 30 patients,
three had adverse cytogenetic abnormalities and failed to
respond to clofarabine treatment. The probability of
responding to treatment was not influenced by age at
diagnosis (p=0.94) or WBC count at diagnosis (p=0.63)
but only by the time interval between the diagnosis and
the first relapse (p=0.02) (Additional file 1: Table S1).
Two of the eight patients (25%) who had previously
received HSCT responded to clofarabine treatment, and
nine (41%) of the 22 patients who had not been previ-
ously transplanted responded.
Among these 30 patients, five received clofarabine as
the first treatment for first bone marrow relapse. These
five patients presented an ORR of 40% (1CR and 1CRp).
They had particularly severe ALL (three of them with a
prior HSCT in CR1, early relapses for all five patients,
and one patient with severe hypodiploidy). However, one
of these five patients who was in a PR after clofarabine
treatment reached CR under further administration of
conventional chemotherapy.
Ten of the 11 responding patients subsequently
received HSCT. The median interval between clofarabine
treatment and HSCT was 3.5 months (range, 3.1-4.3).
Five of the ten transplanted patients were alive at the end
of the study (range, 4.5-22 months).
For the 19 non-responding patients, two were alive at
the end of the study (one was in PR after clofarabine
and the other was being given palliative treatment).
The second group of eight patients treated for high
MRD, had, as expected, a higher survival rate than the first
group. However, the MRD levels did not decrease signifi-
cantly after clofarabine therapy (Table 2). Only one patient
had an improvement of more than one log in MRD (≥10-2
before clofarabine and <10-3 after clofarabine). This patient
was treated in first remission with a combination including
clofarabine. Seven of these eight patients subsequently
received HSCT (only one patient received chemotherapy
after clofarabine treatment and before HSCT) and six of
them were alive at the end of the study. The eighth patient
is alive without having received HSCT.The Kaplan-Meier curves for overall survival (OS) are
shown in Figure 3. The probability of survival one year
after the beginning of clofarabine treatment for the entire
cohort of patients was 38.1% (95%CI: 13.7%-100%).
Patients treated for high MRD had a significantly higher
probability of survival than those treated for relapsed
ALL (with 1 year OS estimated at 87.5%, 95%CI: 67.3%-
100% versus 29.1%, 95%CI: 16.5%-51.4%) (p=0.003).
Among the 30 patients treated for relapse, the 1 year sur-
vival rates for patients who did or did not achieve CR or
CRp were 63.6% (95%CI: 40.7%-99.5%) and 6.6% (95%CI:
1%-42.1%) (p=0.0015), respectively.
Toxicity
Treatment-related toxicities are presented in Table 3.
Only side effects of grade ≥ 3 are reported. Febrile neu-
tropenia grade ≥ 3 was reported in 79% of patients.
Documented infections grade ≥ 3 occurred in nine
patients (24%); six of these nine patients developed septi-
caemia (16%) and three pneumonia (8%). Infectious com-
plications were more frequent in patients treated with
clofarabine in combination than alone (27.5% versus
11%). The median time to neutrophil recovery (defined
as an absolute granulocyte count > 0.5 x 109/l), known
for only 10 of the 11 patients who achieved CR or CRp,
was 22.5 days (range, 15.75-31). Nine patients (24%) had
hepatotoxicity grade 3; eight patients had elevated trans-
aminases (one with CR2 previous HSCT), one patient
had elevated transaminases and hyperbilirubinaemia
(without previous HSCT). No case of veno-occlusive
disease (VOD) was noted. Hepatotoxicity did not differ
significantly between patients treated with clofarabine
alone or in combination. Acute renal failure was diag-
nosed in four patients: one grade 3 and three grade 4
(2 had concomitant multi-organ failure). The deaths of
four patients (10.5%) were potentially associated with
treatment-related complications. All four patients devel-
oped fatal multi-organ failure. One patient presented
with refractory first relapse despite two treatments and
was in a bad general state before starting clofarabine
treatment. Another patient received clofarabine for a
refractory first relapse; he had a severe hypodiploidy
with 25 chromosomes and had previously suffered severe
toxicity during first line therapy after methotrexate treat-
ment (MTHFR mutation). The third patient had received
Figure 3 Overall survival (Kaplan-Meier). Figure 3A Overall
survival for the 38 patients from the beginning of clofarabine
treatment Figure 3B Overall survival for the 30 patients with relapse
of ALL versus the 8 patients treated for a high MRD Figure 3C
Overall survival for the 30 patients with relapse of ALL from start of
treatment by response to treatment.
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undergone previous HSCT in CR2. The fourth patient
presented with a second combined relapse (medullary
and CNS) with paraplegia and blastic meningitis before
the beginning of clofarabine treatment. All these four
patients had received clofarabine in combination and two
of them received concomitant intrathecal chemotherapy.Discussion
This multicentre French retrospective study of 38 patients
treated with clofarabine for ALL shows results below
expectations. In the group of 30 patients who received
clofarabine for an ALL in relapse, the ORR obtained was
only 37%. This value is lower than those of 55% reported
by Hijiya et al. [19] and 56% by Locatelli et al. [20] for
patients treated with a combination of clofarabine, cyclo-
phosphamide and etoposide. However, these phase I
and/or II studies were conducted with patients who met
the eligibility criteria. We obtained better results than
studies with clofarabine used alone, where remission
rates are about 20% [12,14-16]. Two additional studies
have been recently published. The study by O’Connor,
similar to ours, presents the UK experience of clofarabine
in the treatment of relapsed and refractory paediatric
ALL, and they obtain an ORR of 52% [22]. The second is
the phase II study of Hijiya [23], and he reports an ORR
of 44%. However, in our study, most of patients had
advanced disease when clofarabine was administered.
They were heavily pre-treated, with an average of 2.5Table 3 Treatment-related toxicity: NCI CTCAE v4.0
(N=38)
Adverse events (grade ≥3) Number of patients (%)
Febrile neutropenia 30 (79%)




Bacterial sepsis 6 (16%)
Mucositis 4 (10.5%)
Headache 4 (10.5%)
Multi-organ failure 4 (10.5%)
Lung infection 3 (8%)
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refractory to their most recent prior treatment. These
factors may have contributed to the low ORR we
observed. Patients in the studies by O’Connor and
Hijiya had received a mean of only 2 or 2.1 previous
treatments, respectively. Hijiya reports that 60% of the
patients were refractory to their most recent treatment
[23], but no information was provided about refractory
patients in the O’Connor report [22]. Only one study
published recently, reports lower results than ours for
a population of refractory or relapsed ALL [24]. Never-
theless, this result must be interpreted with caution
due to the small number of patients included (9).
Surprisingly, the ORR was similar for refractory
patients (ORR 38%) and those treated with clofarabine
as the first line for a relapse (33%). Also, the ORR was
not better for the five patients treated with clofarabine
for a first relapse and who had only received one prior
treatment (ORR 40%). The results obtained for these five
patients differ from those reported by O’Connor [22].
Effectively, in the same conditions, O’Connor reported
an ORR of 86% (7 patients, 6 CR). Obviously, all these
results must be interpreted with caution due to the
small numbers of patients involved.
Ten of the 11 patients in remission after clofarabine
therapy subsequently underwent HSCT (90%) and five of
these ten were alive (50%) at the end of data analysis with
a median follow-up post HSCT of 13 months (range; 4.5-
22). These data are similar to those reported by other stud-
ies with transplantation rates for patients in remission after
clofarabine of 50% for Locatelli et al.[20], 54% for Hijiya
et al.[19], 63% for Hijiya et al. [23] and 83% for O’Connor
et al. [22] The survival rates after HSCT for responding
patients were 57% (4/7 patients), in the study by Locatelli
with a median follow-up of 8 months after HSCT [20],
and 60% (6/10 patients) in the study by O’Connor, with
a median follow-up of 13 months post HSCT [22]. Fi-
nally, the proportion of patients in remission after clofar-
abine was lower in our cohort than in other studies, but
the post-clofarabine transplantation rate and survival rate
were similar to other published values.
Eight patients in complete remission but with a high
MRD level were treated by clofarabine. But clofarabine
treatment only moderately improved (one log or less)
the MRD levels in four of these eight patients. Most of
these patients were transplanted after clofarabine treat-
ment and the survival rate in this sub-group was high
(87.5% one year after clofarabine). It is not possible to
draw informative conclusions because of the small num-
ber of patients in this subset. Inaba et al. [24] reported
two cases treated for a high MRD, and both showed a
significant improvement of their MRD.
Adverse events associated with clofarabine treatment
are frequent. In our study, clofarabine was generally welltolerated. However, we report four deaths (10.5%) that
could potentially be attributed to the treatment. These
four patients were all in poor condition and developed
multi-organ failure after clofarabine treatment. Hijiya
et al. [19] report a death rate of 8% (2 patients) after
clofarabine treatment, but no deaths were reported by
Locatelli et al. [20] or O’Connor et al. [22]. In their
phase II study, Hijiya et al. [23] reported a substantial
drug-related death rate of 24% (6/25 patients) due not-
ably to severe hepatotoxicity with VOD.
For other adverse events, the incidences we observed
were similar to published data. The incidence of febrile
neutropenia in our study (79%) is comparable with those
reported previously: 60-65% [19,22,23]. We had fewer
documented infections (grade ≥3) than in other studies,
with only nine cases (24%) including six of sepsis. Infec-
tion rates reported previously are in a range of 30-72%
[19,20,22] depending on supportive therapy and infection
prophylaxis. Thus, infectious complications are frequent
with clofarabine treatment. To decrease their incidence,
prophylactic treatments against bacterial and fungal infec-
tions with an active monitoring of patients are required.
Hepatic toxicity is frequent when clofarabine is used
as single agent or in combination [12,14,18]. Some
severe and life-threatening cases of hepatic toxicity were
described by Hijiya et al. [19,23] (3 VOD, 1 hyperbilirubi-
naemia). In our study, grade 3 hepatotoxicity occurred in
nine patients (24%; 1 hyperbilirubinaemia and elevated
transaminase and 8 elevated transaminases), but there
were no cases of VOD. The hepatotoxicity rate in our
study was not higher among patients with previous
HSCT than among those without HSCT.Conclusion
This French “real life” experience of clofarabine treatment
for refractory or relapsed ALL reveals slightly lower re-
sponse rates than previously reports. Our remission rates
were somewhat lower than those presented in other stud-
ies. However, we observed a transplantation rate and sur-
vival rate similar to those of other published studies. The
other common idea to use clofarabine for MRD reduction
in the pre-transplant phase is not substantiated here.
Nevertheless, the numbers of patients studied are small,
and their disease severe, such that additional studies are
required to determine the best use of clofarabine. It could
be informative to use clofarabine at an earlier stage of
the disease, to assess if it is more effective earlier dur-
ing disease progression. Indeed, the next International
Study on Relapsed ALL will randomize the use of combi-
nations including clofarabine for patients at high risk.
Clofarabine is associated with a high rate of infection
and hepatotoxicity. Deaths related to treatment were
observed. These risks must be taken into consideration
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cost of this new drug makes it essential to conduct com-
parative and prospective evaluations of its risk-benefit
ratio.Additional file
Additional file 1: Table S1. Predictive factors of remission for 30
patients treated with clofarabine for relapsed or refractory ALL.
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